LANSING, Mich., Feb. 18, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today the National Labor Relations Board (NLRB) has withdrawn its unfair labor practices claim against the Company. The claim was withdrawn following a mutual agreement, with no admission of wrongdoing by Neogen.
In the coming weeks, Lansing warehouse shipping clerks and material handling employees will have the opportunity to vote in an election to determine whether they wish to unionize.
"At Neogen, we are dedicated to fostering a supportive and equitable workplace where employees feel valued and heard," said Amy Rocklin, Chief Legal and Compliance Officer. "We respect our employees' rights and we prioritize a positive work environment. Neogen remains committed to supporting our employees throughout this process and will continue to comply fully with all legal obligations related to the election."
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.14 |
Daily Change: | 0.16 3.21 |
Daily Volume: | 3,028,364 |
Market Cap: | US$1.120B |
May 13, 2025 January 21, 2025 January 10, 2025 December 17, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load